Stockreport

Moleculin MIRACLE Trial Delivers 40% Preliminary Blinded CRc Rate (n=30)

Moleculin Biotech, Inc.  (MBRX) 
Last moleculin biotech, inc. earnings: 8/16 05:35 pm Check Earnings Report
US:NASDAQ Investor Relations: moleculin.com/investors
PDF Preliminary blinded CR rate showed 67% improvement over historical cytarabine response Roughly 35% of the subjects treated to date represent ventoclax regimen failuresF [Read more]